{"certainAgreement":{"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Amendment 3 (7 March 2007) allowed participants to switch from BID to QD dosing. Therefore, results for BID summarized by treatment group after Year 2 may not be a complete reflection of the BID experience and should be interpreted with this in mind."},"pointOfContact":{"email":"Clinical.Trials@bms.com","organization":"Bristol-Myers Squibb","title":": Bristol-Myers Squibb Study Director"}}